
According to data from Benzinga Pro, during Q1, Lyra Therapeutics's (NASDAQ:LYRA) reported sales totaled $5.37 million. Despite a 48.51% increase in earnings, the company posted a loss of $7.01 million. In Q4, Lyra Therapeutics brought in $271.00 thousand in sales but lost $13.62 million in earnings.